Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis

Medicine and Dentistry

• Blinatumomab 100%
• Hematopoietic Stem Cell 66%
• Stem Cell Transplant 66%
• Overall Survival 50%
• Minimal Residual Disease 50%
• Patient 50%
• Adverse Event 33%
• Compassionate Use 33%
• Therapeutic Procedure 33%
• Incidence 33%
• Pediatrics 33%
• Age 16%
• Precursor 16%
• Hazard Ratio 16%
• Survival Rate 16%
• Continuous Infusion 16%
• Acute Lymphoblastic Leukemia 16%
• Recurrence Free Survival 16%
• Acute B-Cell Lymphoblastic Leukemia 16%
• Cytokine Release Syndrome 16%
• B Cell 16%
• Analysis 16%
• Arm 16%
• Child 16%